Evaluating the Effects of Colonization with Multidrug-Resistant Bacteria on the Outcomes of Induction Chemotherapy in Patients with Acute Leukemia: A Prospective Analysis

Abstract

Introduction The presence of multi-drug resistant (MDR) bacteria has been linked to higher rates of morbidity and mortality in patients with acute leukemia.

Objective This prospective study aimed to evaluate the prevalence of MDR bacteria in stool samples of patients undergoing induction chemotherapy for acute leukemia and to explore its association with clinical outcomes.

Materials and Methods The study recruited 200 patients, aged 1-60 years, with newly diagnosed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who were scheduled to receive intensive induction chemotherapy. Stool samples were obtained on days 1 and 15 of the induction phase, and standard bacterial culture methods were used to determine culture and sensitivity.

Results Two hundred patients were enrolled from January 2018 to March 2020. On day 1, 35.7% of the stool cultures were positive, with all identified bacteria being MDR. On day 15, 36.7% of the samples were positive for MDR bacteria. MDR E. coli and MDR Enterococcus faecium were the most common organisms isolated in the stool culture. The detection of MDR bacteria in day 15 stool cultures was significantly associated with an increased risk of infections, admissions to the intensive care unit, mortality, and failure to achieve remission.

Conclusion These findings indicate that monitoring stool colonization with MDR bacteria during induction chemotherapy could be crucial for identifying patients at elevated risk of adverse outcomes and optimizing antimicrobial strategies.

Keywords

infection - acute leukemia - multidrug resistant - chemotherapy - stool culture

Authors' Contributions

Data collection was performed by M.C., V.R., V.V., P.B.B.L., D.G., J.P.K., and P.G. The data analysis was performed by V.R. and S.R. The management of patients in the trial was handled by V.R., D.G., P.B.B.L., J.P.K., and P.G.

Data Availability Statement

The data cannot be shared due to patient privacy and ethical issues.

Presentation

This article was presented as an oral presentation at the SIOP 2023 Annual Meeting and poster presentation at the MASCC 2023 Annual Meeting.

Publikationsverlauf

Artikel online veröffentlicht:
10. Februar 2025

• References

• 1 Radhakrishnan V, Vijaykumar V, Ganesan P, Rajendranath R, Trivadi G, Tenali S. Bloodstream infections in pediatric patients at Cancer Institute, Chennai. Indian J Cancer 2014; 51 (04) 418-419
• 2 Radhakrishnan V, Thampy C, Ganesan P. et al. Acute myeloid leukemia in children: experience from tertiary cancer centre in India. Indian J Hematol Blood Transfus 2016; 32 (03) 257-261
• 3 Radhakrishnan V, Bakhshi S, Kayal S. et al. Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial. Blood Cancer J 2022; 12 (09) 131
• 4 Murali NA, Ganesan P, Vijayakumar V. et al. Increasing incidence of multidrug-resistant gram-negative septicaemia during induction therapy of acute myeloid leukaemia. J Hosp Infect 2016; 93 (03) 314-315
• 5 Mishra AK, Krishnan S, Bhattacharyya A. et al. High treatment related mortality due to infection remains a major challenge in the management of high-grade B-cell Non-Hodgkin Lymphoma in children in developing countries: experience from a tertiary cancer center in Eastern India. Pediatr Hematol Oncol J 2022; 7 (02) 54-60
• 6 Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004; 39 (02) 219-226
• 7 Vaishnavi C. Translocation of gut flora and its role in sepsis. Indian J Med Microbiol 2013; 31 (04) 334-342
• 8 Sougiannis AT, VanderVeen BN, Davis JM, Fan D, Murphy EA. Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiol Gastrointest Liver Physiol 2021; 320 (05) G712-G719
• 9 Aslam B, Wang W, Arshad MI. et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist 2018; 11: 1645-1658
• 10 Murray CJL, Ikuta KS, Sharara F. et al; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399 (10325): 629-655
• 11 Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist 2019; 12: 3903-3910
• 12 Shankar K, Radhakrishnan V, Vijayakumar V. et al. Prevalence of multi-drug resistant organisms in stool of paediatric patients with acute leukaemia and correlation with blood culture positivity: a single institution experience. Pediatr Blood Cancer 2018; 65 (01) 26740
• 13 Salifu N, Narula G, Prasad M, Biswas S, Kelkar R, Banavali S. Correlation between multidrug-resistant bacteria colonization and bloodstream infections in children with hematolymphoid malignancies at a tertiary cancer center in India. Indian J Med Paediatr Oncol 2021; 42 (01) 61-66
• 14 Radhakrishnan V, Lagudu PBB, Gangopadhyay D. et al. Neutropenic versus regular diet for acute leukaemia induction chemotherapy: randomised controlled trial. BMJ Support Palliat Care 2022; 12 (04) 421-430
• 15 Das N, Banavali S, Bakhshi S. et al. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials 2022; 23 (01) 102
• 16 Möricke A, Reiter A, Zimmermann M. et al; German-Austrian-Swiss ALL-BFM Study Group. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111 (09) 4477-4489
• 17 Bajel A, George B, Mathews V. et al. Adult ALL: treatment outcome and prognostic factors in an Indian population using a modified German ALL (GMALL) protocol. Leukemia 2007; 21 (10) 2230-2233
• 18 Burnett AK, Russell NH, Hills RK. et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31 (27) 3360-3368
• 19 Ziegler R, Johnscher I, Martus P, Lenhardt D, Just HM. Controlled clinical laboratory comparison of two supplemented aerobic and anaerobic media used in automated blood culture systems to detect bloodstream infections. J Clin Microbiol 1998; 36 (03) 657-661
• 20 Ling TKW, Liu ZK, Cheng AFB. Evaluation of the VITEK 2 system for rapid direct identification and susceptibility testing of gram-negative bacilli from positive blood cultures. J Clin Microbiol 2003; 41 (10) 4705-4707
• 21 Sievert DM, Ricks P, Edwards JR. et al; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34 (01) 1-14
• 22 Magiorakos AP, Srinivasan A, Carey RB. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18 (03) 268-281
• 23 Gundluru SB, Roy PS, Biswal M. et al. Isolation of multidrug-resistant organisms in surveillance stool culture at diagnosis fails to predict mortality or subsequent sepsis due to multidrug-resistant organisms in children with acute leukemia: a single-center, prospective, observational study. Indian J Pediatr 2023; (e-pub ahead of print)
• 24 Fletcher S. Understanding the contribution of environmental factors in the spread of antimicrobial resistance. Environ Health Prev Med 2015; 20 (04) 243-252
• 25 Papanicolas LE, Gordon DL, Wesselingh SL, Rogers GB. Not just antibiotics: is cancer chemotherapy driving antimicrobial resistance?. Trends Microbiol 2018; 26 (05) 393-400
• 26 Masterton RG. Antibiotic de-escalation. Crit Care Clin 2011; 27 (01) 149-162
• 27 Hurley JC. Selective digestive decontamination, a seemingly effective regimen with individual benefit or a flawed concept with population harm?. Crit Care 2021; 25 (01) 323